Sélectionner la langue

Mon panier

Complement C5

Complement C5 Informations sur la molécule

Nom anglais	Complement C5	Nombre de médicaments commercialisés	8
Nombre de médicaments cliniques	19	Alias de la cible	C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D
Phase de R&D la plus avancée	Approved

Nom anglais	Complement C5
Alias de la cible	C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D
Nombre de médicaments commercialisés	8
Nombre de médicaments cliniques	19
Phase de R&D la plus avancée	Approved

Complement C5 Liste de produits

Attribut
Protein (11)Kits (1)
Bibliothèque de produits
En ligne (12)
Espèces
Human (6)Mouse (1)Rat (2)Cynomolgus (2)Rabbit (1)
Étiquette
His Tag (7)His Tag & Avi Tag (3)Fc Tag (1)- (1)
Marqueur
Unconjugated (8)Biotin-labeled (3)- (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT CO5-H52Ha	Human	HEK293	Human Complement C5 Protein, His Tag, low endotoxin (MALS verified)	Ajouter au panier
HOT CO5-H82E9	Human	HEK293	Biotinylated Human Complement C5 Protein, His,Avitag™ (MALS verified)	Ajouter au panier
HOT CO5-M52H4	Mouse	HEK293	Mouse Complement C5 Protein, His Tag	Ajouter au panier
HOT CO5-R52H5	Rat	HEK293	Rat Complement C5 Protein, His Tag	Ajouter au panier
CEA-B241	Human	-	Human Complement C5 ELISA Kit	Ajouter au panier
CO5-H5253	Human	HEK293	Human Complement C5 Protein, Fc Tag	Ajouter au panier
CO5-H52H7	Human	HEK293	Human Complement C5 (w917s) Protein, His Tag (MALS verified)	Ajouter au panier
CO5-H52Hx	Human	HEK293	Human Complement C5 (R885H) Protein, His Tag	Ajouter au panier
CO5-C52Hx	Cynomolgus	HEK293	Cynomolgus Complement C5 Protein, His Tag (MALS verified)	Ajouter au panier
CO5-C82E3	Cynomolgus	HEK293	Biotinylated Cynomolgus Complement C5 Protein, His,Avitag™ (MALS verified)	Ajouter au panier

Quantité totale12

Complement C5Contexte de la molécule

Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Complement C5Alias de la molécule

Complement C5,C5,CPAMD4

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Eculizumab biosimilar (CinnaGen)		Phase 3 Clinical	Cinnagen	Hemoglobinuria, Paroxysmal	Details
Eculizumab biosimilar (IBC GENERIUM)		Phase 3 Clinical	Ibc Generium	Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome	Details
Gefurulimab	TPP-2511; ALXN-1720; CON-9978	Phase 3 Clinical	Alexion Pharmaceuticals Inc	Myasthenia Gravis; Proteinuria	Details
Eculizumab biosimilar (Biocad)	BCD-148	Phase 3 Clinical	BIOCAD JSC	Hemoglobinuria, Paroxysmal	Details
Cemdisiran	ALN-CC5; AD-62643; ALN-62643; L96	Phase 3 Clinical	Alnylam Pharmaceuticals Inc	Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Myositis; Atypical Hemolytic Uremic Syndrome; Myositis, Inclusion Body; Geographic Atrophy; Macular Degeneration	Details
Nomacopan	EV-576; rEV-576; rVA576	Phase 3 Clinical	Evolutec	Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Conjunctivitis, Allergic; Pemphigoid, Bullous; Geographic Atrophy	Details
Tesidolumab	NOV-4; LFG-316	Phase 2 Clinical	Novartis Pharma Ag, Morphosys Ag	Rejection of renal transplantation; Uveitis, Intermediate; Hemoglobinuria, Paroxysmal; Wet Macular Degeneration; Geographic Atrophy; Uveitis, Posterior; Panuveitis; Macular Degeneration	Details
OCUL-101	OCUL101	Phase 2 Clinical		Diabetic macular oedema; Geographic Atrophy; Retinal Neovascularization; Macular Degeneration	Details
KRIYA-825	KRIYA-825; VV-14295	Phase 2 Clinical	Kriya Therapeutics Inc	Geographic Atrophy	Details
LP-005	RX-001; LP-005	Phase 2 Clinical	Longbio Pharma (Suzhou) Co Ltd	Myasthenia Gravis; Peripheral Nervous System Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Amyotrophic Lateral Sclerosis	Details
Vensobafusp alfa	P014; KP-104	Phase 2 Clinical	Kira Pharmaceuticals LLC	Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Thrombotic Microangiopathies; Lupus Erythematosus, Systemic; Glomerulonephritis	Details
Omoprubart	CAN-106	Phase 2 Clinical	Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd	Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn	Details
IM-101	IM-101	Phase 1 Clinical	ImmunAbs Inc	Autoimmune Diseases	Details
ALXN-5500	ALXN-5500	Phase 1 Clinical	Alexion Pharmaceuticals Inc	Hemoglobinuria, Paroxysmal	Details
RLYB-116	RLYB-116	Phase 1 Clinical	Rallybio Llc	Hematologic Diseases; Autoimmune Diseases; Immune System Diseases; Inflammation	Details
NM3086	NM3086; NM-3086	Phase 1 Clinical	NovelMed Therapeutics Inc	Hemoglobinuria, Paroxysmal	Details
Eculizumab biosimilar (Turgut Ardika)	TUR03; TUR-03	Phase 1 Clinical	Turgut Ardika Pty Ltd		Details
EA-5	EA5; EA-5	Phase 1 Clinical	Shanghai Lanyi Pharmaceutical Technology Co Ltd	Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Kidney Diseases	Details
eculizumab biosimilar(Isu Abxis)	ISU-305	Phase 1 Clinical	Isu Abxis Co Ltd	Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Avacincaptad pegol	ARC-1905; ARC-187	Approved	Archemix Corp	Zimura, Izervay	United States	Macular Degeneration; Geographic Atrophy	Iveric Bio Inc, Astellas Pharma Inc	2023-08-04	Polypoidal choroidal vasculopathy; Geographic Atrophy; Macular Degeneration	Details
Zilucoplan Sodium	RA-101495-SC; RA-101495; ZLP-AI	Approved	Ra Pharmaceuticals Inc, Ucb Sa	ZILBRYSQ, Zilbrysq	Japan	Myasthenia Gravis	Ucb Japan Co Ltd	2023-09-25	Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases; Amyotrophic Lateral Sclerosis	Details
Crovalimab	RO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689	Approved	Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd	派圣凯, Piasky	Mainland China	Hemoglobinuria, Paroxysmal	Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc	2024-02-06	Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Anemia, Sickle Cell	Details
Ravulizumab	ALXN-1210; ALXN-1810	Approved	Alexion Pharmaceuticals Inc, Xencor Inc	Ultomiris	United States	Hemoglobinuria, Paroxysmal	Alexion Pharmaceuticals Inc	2018-12-21	Respiratory Distress Syndrome, Adult; Amyotrophic Lateral Sclerosis; Acute Lung Injury; Renal Insufficiency, Chronic; Neuromyelitis Optica; Pneumonia, Viral; Delayed Graft Function; Lupus Nephritis; Atypical Hemolytic Uremic Syndrome; Acute Kidney Injury; Myasthenia Gravis; Thrombotic Microangiopathies; Heart Diseases; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Dermatomyositis; Rejection of renal transplantation	Details
Eculizumab	LEX-98; h-5G1.1; 5G1-1; HAL-1	Approved	Alexion Pharmaceuticals Inc	Soliris, 舒立瑞	United States	Hemoglobinuria, Paroxysmal	Alexion Pharmaceuticals Inc	2007-03-16	Neuromyelitis Optica; Macular Degeneration; Kidney Failure, Chronic; Diabetes Mellitus; Urea Cycle Disorders, Inborn; Thrombocytopenia; Guillain-Barre Syndrome; Asthma; Glomerulonephritis, Membranoproliferative; Nasopharyngeal Carcinoma; Parturition; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Rejection of organ transplantation; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; Rejection of renal transplantation; End Stage Liver Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; HELLP Syndrome	Details
Pozelimab	REGN-3918	Approved	Regeneron Pharmaceuticals Inc	VEOPOZ	United States	Protein-Losing Enteropathies	Regeneron Pharmaceuticals Inc	2023-08-18	Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies	Details
Eculizumab biosimilar (Amgen)	ABP-959	Approved	Amgen Inc	BKEMV	United States	Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome	Amgen Inc	2024-05-28	Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome	Details
Eculizumab biosimilar (Samsung Bioepis)	SB-12; AM004; AMT-904; SB12	Approved	Samsung Bioepis Co Ltd	Epysqli, EPYSQLI	EU	Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal	Samsung Bioepis Nl Bv	2023-05-26	Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome	Details

Avis sur les produits

1***32022-08-10
0Mettre un like
Cynomolgus Complement C5 Protein, His Tag (MALS verified)
I tried to express this product myself and it didn’t work, so I purchased ACRO’s products for antibody screening. The binding activity is very good and method establishment is also going very smoothly. There is also complete technical support available to help us solve any problems that arise during our experiments.

Informations sur la molécule
Liste de produits
Informations sur les médicaments commercialisés
Avis sur les produits
Informations sur les médicaments cliniques

[North America]: +1 800-810-0816 [Switzerland]: +41 800 040 012 [Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel

Email：order@acrobiosystems.com

Nous rejoindre Mentions légales Plan du site Politique de confidentialité Terms and Conditions

Retour sur le site web

Nous contacter

+41 800 040 012

order.fr@acrobiosystems.com
tech.fr@acrobiosystems.com